Debiopharm and Cambridge Antibody Technology enter into an exclusive agreement to develop and market SC-1 for gastric carcinomas
The Debiopharm Group and Cambridge Antibody Technology (CAT) have entered into an exclusive worldwide licensing agreement to develop and commercialise SC-1 and all derivative products generated by the use of the SC-1 Technology. SC-1, developed by Debiopharm, is a fully human monoclonal IgM antibody that targets CD55SC-1, a cell surface receptor specifically expressed on gastric carcinoma cells. Under the terms of the agreement, Debiopharm will receive upfront and milestone payments from CAT as well as royalties on potential future sales.
SC-1 has completed an academic Phase I/II study in 51 resectable gastric cancer patients. SC-1 has been granted orphan drug designation by the US FDA for gastric cancer.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.